An AI model can accurately flag EGFR mutations in lung adenocarcinoma using routine pathology slides, reducing the need for rapid genetic tests.
Key Details
- 1Researchers from Mount Sinai, Memorial Sloan Kettering, and collaborators published results in Nature Medicine on July 9, 2025.
- 2The AI model predicts EGFR mutations from H&E-stained pathology slides of lung adenocarcinoma.
- 3A live 'silent trial' at Memorial Sloan Kettering showed the model could reduce rapid genetic testing by over 40%.
- 4The model was trained and validated on the largest multi-institutional dataset of matched slides and sequencing results from the US and Europe.
- 5Preserving tissue by avoiding unnecessary rapid tests allows for more comprehensive genomic sequencing.
- 6Work is ongoing to broaden the model's biomarker detection and deploy it in more healthcare settings.
Why It Matters
This study demonstrates the practical integration of AI in pathology workflows, expediting precision therapy decisions and optimizing tissue usage in lung cancer diagnostics. It signals a major step toward AI-driven personalization in oncology, with potential to improve both efficiency and patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.